CN112111538A - 一种可调节肠促胰岛素定位释放的功能糖及其制备方法 - Google Patents
一种可调节肠促胰岛素定位释放的功能糖及其制备方法 Download PDFInfo
- Publication number
- CN112111538A CN112111538A CN202010995718.4A CN202010995718A CN112111538A CN 112111538 A CN112111538 A CN 112111538A CN 202010995718 A CN202010995718 A CN 202010995718A CN 112111538 A CN112111538 A CN 112111538A
- Authority
- CN
- China
- Prior art keywords
- functional
- functional sugar
- incretins
- release
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000000346 sugar Nutrition 0.000 title claims abstract description 62
- 239000000859 incretin Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 26
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 229920002472 Starch Polymers 0.000 claims abstract description 20
- 235000019698 starch Nutrition 0.000 claims abstract description 20
- 239000008107 starch Substances 0.000 claims abstract description 20
- 229920001353 Dextrin Polymers 0.000 claims abstract description 18
- 239000004375 Dextrin Substances 0.000 claims abstract description 18
- 235000019425 dextrin Nutrition 0.000 claims abstract description 18
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 15
- 230000001105 regulatory effect Effects 0.000 claims abstract description 10
- 230000007062 hydrolysis Effects 0.000 claims abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 6
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 5
- 239000000758 substrate Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000001976 enzyme digestion Methods 0.000 claims description 17
- 229920000858 Cyclodextrin Polymers 0.000 claims description 14
- 102000006833 Multifunctional Enzymes Human genes 0.000 claims description 11
- 108010047290 Multifunctional Enzymes Proteins 0.000 claims description 11
- 238000007142 ring opening reaction Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 102000004139 alpha-Amylases Human genes 0.000 claims description 6
- 108090000637 alpha-Amylases Proteins 0.000 claims description 6
- 229940024171 alpha-amylase Drugs 0.000 claims description 6
- GUBGYTABKSRVRQ-ASMJPISFSA-N alpha-maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-ASMJPISFSA-N 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 6
- 239000000845 maltitol Substances 0.000 claims description 6
- 235000010449 maltitol Nutrition 0.000 claims description 6
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 6
- 229940035436 maltitol Drugs 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 108010028688 Isoamylase Proteins 0.000 claims description 5
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 claims description 5
- 102400000472 Sucrase Human genes 0.000 claims description 5
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 108010042194 dextransucrase Proteins 0.000 claims description 5
- 235000011073 invertase Nutrition 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 230000037213 diet Effects 0.000 claims description 4
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000310 Alpha glucan Polymers 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 108010035855 neopullulanase Proteins 0.000 claims description 3
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims 2
- 235000020880 diabetic diet Nutrition 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 12
- 208000017667 Chronic Disease Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 108020003175 receptors Proteins 0.000 abstract description 4
- 230000036528 appetite Effects 0.000 abstract description 3
- 235000019789 appetite Nutrition 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 230000030136 gastric emptying Effects 0.000 abstract description 2
- 230000001766 physiological effect Effects 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 230000006098 transglycosylation Effects 0.000 abstract description 2
- 238000005918 transglycosylation reaction Methods 0.000 abstract description 2
- 230000037221 weight management Effects 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 22
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 22
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 229920000856 Amylose Polymers 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000000413 hydrolysate Substances 0.000 description 12
- 150000008163 sugars Chemical class 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- 229920000945 Amylopectin Polymers 0.000 description 9
- 239000001116 FEMA 4028 Substances 0.000 description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 9
- 229960004853 betadex Drugs 0.000 description 9
- 239000003629 gastrointestinal hormone Substances 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000008213 purified water Substances 0.000 description 8
- 230000035764 nutrition Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108010009736 Protein Hydrolysates Proteins 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 4
- 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- -1 resveratrol Natural products 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 1
- 101710142157 Stanniocalcin-1 Proteins 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/16—Preparation of compounds containing saccharide radicals produced by the action of an alpha-1, 6-glucosidase, e.g. amylose, debranched amylopectin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种可调节肠促胰岛素定位释放的功能糖及其制备方法,属于现代营养食品技术领域。本发明以淀粉类糊精和功能单糖为底物,通过糖链水解转苷与受体介导技术制备得到可调节肠促胰岛素定位释放的功能糖。本发明方法具有工艺绿色环保、加工成本低等优点,所制备产品生理活性显著,具有调控食欲和胃排空速率功能,涉及功能食品、慢病干预、体重管理等多个领域。
Description
技术领域
本发明属于现代营养食品技术领域,具体涉及一种可调节肠促胰岛素定位释放的功能糖及其制备方法。
背景技术
近年来与膳食结构和生活习惯相关的非传染性慢性病及代谢综合症患者剧增。这些慢性疾病及其危险因素水平的快速上升趋势,已成为威胁我国人民健康的突出问题。世界卫生组织(WHO)对影响人类健康因素的评估结果表明,膳食营养因素(13%)对健康的作用仅次于遗传因素(15%),而大于医疗因素(8%)。因此,膳食营养干预调控具有重要市场意义和前景。
当前,世界各国重视食品营养健康科技创新与产业发展,以精准个性化营养健康调控为代表的创新关键技术已成为产业热点和难点。已有专家正在将现代分子营养设计等前沿制造技术靶向生产精准营养与个性化食品,开发出系列高品质健康食品。其中,功能糖集营养、保健、食疗于一体,广泛应用于食品、保健品、饮料等领域。作为益生元,功能糖具有改善肠道微生态、促进脂质、蛋白质与矿物类代谢等功能,近年来国际上颇为流行,代表性产品为低聚异麦芽糖、低聚果糖、低聚半乳糖产品为主。同时,胰高血糖素样肽-1(GLP-1)是由存在于小肠末端和结肠近端L-细胞所分泌的肠促胰素,可调控机体血糖反应和食欲等诸多生理过程,对预防代谢综合症和身体健康具有重要作用。食品大分子营养素的消化产物包括单糖、氨基酸、脂肪酸以及白藜芦醇、咖啡多酚、葡萄籽原花青素等植物营养化学物均能刺激GLP-1的分泌,但正常条件下,大多数食品营养素和其他组分是在小肠的近端区域被消化和吸收,几乎不可能到达小肠末端。
发明内容
本发明的目的旨在提供一种可用于调节肠促胰岛素定位释放的功能糖及其加工方法。本发明方法具有工艺绿色环保、加工成本低等优点,所制备产品生理活性显著,具有调控食欲和胃排空速率功能,该功能糖在小肠末端刺激L细胞分泌GLP-1并通过脑肠轴机制来实现,涉及功能食品、慢病干预、体重管理等多个领域。
本发明目的通过如下技术方案实现:
一种制备可调节肠促胰岛素定位释放的功能糖的方法,所述方法是将淀粉类糊精供体和功能单糖受体分散于水中,混匀,形成混合液;然后加入多功能酶制剂进行酶解,结束后,即可获得可调节肠促胰岛素定位释放的功能糖;
其中,所述的功能单糖受体选自如下任意一种或多种:2-脱氧葡萄糖、甘露糖、岩藻糖、阿洛糖、海藻糖、塔格糖、麦芽糖醇、甘露醇;
多功能酶制剂选自如下任意一种或多种:水解糖酶家族70、13的蔗糖-4-葡糖基转移酶、蔗糖-6-葡糖基转移酶、蔗糖-1,6(3)-α-葡聚糖6(3)-葡糖基转移酶、α-4,6-葡糖基转移酶、α-4,3-葡糖基转移酶、罗伊氏蔗糖酶。
在本发明一种实施方式中,所述淀粉类糊精是通过采用如下方法制备得到:采用对淀粉链进行酶切水解;或者对环化糊精进行开环解聚获得线性糊精。所述酶切水解涉及的酶为:α-淀粉酶或者异淀粉酶。所述环化糊精进行开环解聚涉及的酶为新普鲁兰酶。所述酶切水解中添加150-200U/gα-淀粉酶,或者5-10U/g异淀粉酶。所述环化糊精中添加80-100U/g新普鲁兰酶。
在本发明一种实施方式中,所述混合液中淀粉类糊精供体的浓度为5-50mg/mL。
在本发明一种实施方式中,所述混合液中淀粉类糊精供体与功能单糖受体的质量比为1:1-1:20。
在本发明一种实施方式中,所述多功能酶制剂相对底物淀粉类糊精的添加量为100-500U/g。
在本发明一种实施方式中,所述酶解是在30-80℃下反应3-24h。
在本发明一种实施方式中,所述方法还包括:酶解结束后,灭酶活、膜滤分级、离心处理。
在本发明一种实施方式中,多功能酶制剂为来源于水解糖酶家族70或13的蔗糖-4-葡糖基转移酶、蔗糖-6-葡糖基转移酶、蔗糖-1,6(3)-α-葡聚糖6(3)-葡糖基转移酶、α-4,6-葡糖基转移酶、α-4,3-葡糖基转移酶、罗伊氏蔗糖酶等中一种或多种;上述酶可来源于古生菌、细菌或者植物。
在本发明的一种实施方式中,所述方法具体包括如下步骤:
将淀粉类糊精溶解于水中,配成质量百分比浓度5-50mg/mL的淀粉类糊精供体溶液;按照1:1-1:20比例将受体功能单糖添加到淀粉类糊精供体溶液,混合均匀;置于30-80℃水浴加热20-60min后,然后加入100-500U/g多功能酶制剂并保温反应3-24h;加热灭酶活、膜滤分级、离心处理,将所获得上清液进行干燥即得目标产物。
本发明的第二个目的是提供一种可调节肠促胰岛素定位释放的功能糖。
在本发明的一种实施方式中,所述可调节肠促胰岛素定位释放的功能糖中功能单糖受体在淀粉类糊精上的接枝率为40-80%。
在本发明的一种实施方式中,所述可调节肠促胰岛素定位释放的功能糖的平均分子尺寸为DP 3-30。
在本发明的一种实施方式中,所述可调节肠促胰岛素定位释放的功能糖在L细胞系模型中刺激肠道激素GLP-1释放水平大于1.05pM/μg蛋白。
本发明的第三个目的是将上述可调节肠促胰岛素定位释放的功能糖应用于制备糖尿病特膳食品、轻断食产品、运动食品、低升糖食品等新型营养品中。
本发明有以下优点:
1)本发明充分利用我国资源丰富的淀粉类糊精和功能单糖,以淀粉类糊精和功能单糖为底物,通过糖链水解转苷与受体介导技术制备得到可调节肠促胰岛素定位释放的功能糖,提升现代食品营养品质,实现个性化和营养精准食品的制造。
2)本发明功能糖制备过程步骤简便,反应条件可控,实现了连续化和低成本绿色生产。
3)本发明功能糖产品具有营养干预健康调控功能,能够在L细胞系模型中刺激肠道激素GLP-1释放水平达1.15pM/μg蛋白以上。本发明功能糖既可作为终端产品直接投放市场供消费者食用,还可用作于糖尿病特膳食品、轻断食产品、运动食品、低升糖食品的原料,市场前景广阔,经济和社会效益显著。
附图说明
图1为功能糖分子尺寸分布液相图。
具体实施方式
下面结合实例进一步阐明本发明的内容,但本发明所保护的内容不仅仅局限于下面的实例。
功能糖平均分子尺寸采用高效液相色谱测定:色谱条件为:将制备得到功能糖用0.22μm针头式滤膜过滤,然后采用HPLC方法进行检测。色谱柱:Zorbax Carbohydrate柱(4.6×150mm),检测器:示差折光检测器,流动相:乙腈:水=75:25(v:v),流速1.0mL/min,柱温35℃,上样体积10μL。
肠道激素GLP-1测定:采用小鼠内分泌细肠胞系STC-1,首先在含有10%胎牛血清和1%青霉素-链霉素的DMEM杜氏改良Eagle培养基中进行培养,将洗涤培养基用含消化上清液(稀释到消化淀粉产品为20-200mmol/L)的Hank's平衡盐溶液代替,保温培养2小时后收集样品,加入蛋白酶抑制PMSF(100μmol/L),采用ELISA试剂盒分析GLP-1水平
接枝率测定过程、计算方法:采用液相色谱方法监测反应过程中游离功能单糖含量。接枝率(%)=(1–反应后游离单糖含量/反应前游离单糖含量)×100。
酶来源说明:下述实施例涉及到的商业化α-淀粉酶液、α-4,3-葡糖基转移酶、新普鲁兰酶、蔗糖-6-葡糖基转移酶、商业化异淀粉酶、罗伊氏蔗糖酶购置于爱尔兰Megzyme公司;或者根据Microbial Starch-Converting Enzymes:Recent Insights andPerspectives,ComprehensiveReviews in Food Science and Food Safety,2018,17:1238-1260现有报道的已知方法自制得到。
实施例1
直链淀粉链酶切水解产物的制备过程:玉米直链淀粉融于纯净水配成质量百分比10%的溶液,添加200U/g的商业化α-淀粉酶液,在50℃水浴反应2h,加热灭酶活、离心处理后,将上清液喷雾干燥即得直链淀粉链酶切水解产物。
称取一定质量(1g)的直链淀粉链酶切水解产物溶解于纯净水配成质量百分比浓度10mg/mL,按照1:1比例将受体麦芽糖醇添加到上述溶液,混合均匀;置于35℃水浴加热40min后,然后加入100U/g的α-4,3-葡糖基转移酶并保温反应24h;加热灭酶活、膜滤分级、离心处理,将所获得上清液进行干燥即得功能糖。
所得功能糖的平均分子尺寸为DP12.5,接枝率为45%。
所得功能糖在L细胞系模型中刺激肠道激素GLP-1释放水平1.21pM/μg蛋白。
实施例2
直链淀粉链酶切水解产物的制备过程:玉米直链淀粉融于纯净水配成质量百分比10%的溶液,添加150U/g的商业化α-淀粉酶液,在50℃水浴反应1h,加热灭酶活、离心处理后,将上清液喷雾干燥即得直链淀粉链酶切水解产物。
称取一定质量(0.5g)的直链淀粉链酶切水解产物溶解于纯净水配成质量百分比浓度10mg/mL,按照1:1比例将受体麦芽糖醇添加到上述溶液,混合均匀;置于35℃水浴加热40min后,然后加入100U/g的α-4,6-葡糖基转移酶并保温反应24h;加热灭酶活、膜滤分级、离心处理,将所获得上清液进行干燥即得功能糖。
所得功能糖的平均分子尺寸为13.6,接枝率为54%。
所得功能糖在L细胞系模型中刺激肠道激素GLP-1释放水平1.15pM/μg蛋白。
实施例3
β-环糊精开环解聚产物:商业化β-环糊精融于纯净水配成质量百分比2%的溶液,添加80U/g新普鲁兰酶,在40℃水浴反应6h,加热灭酶活、离心处理后,将上清液喷雾干燥即得β-环糊精开环解聚产物。
称取一定质量的β-环糊精开环解聚产物溶解于纯净水配成质量百分比浓度50mg/mL,按照1:10比例将甘露糖添加到上述溶液,混合均匀;置于70℃水浴加热20min后,然后加入500U/g蔗糖-6-葡糖基转移酶并保温反应10h;加热灭酶活、膜滤分级、离心处理,将所获得上清液进行干燥即得功能糖。
所得功能糖的平均分子尺寸为DP8.3,接枝率为42%。
所得功能糖在L细胞系模型中刺激肠道激素GLP-1释放水平1.15pM/μg蛋白。
实施例4
支链淀粉链酶切水解产物的制备过程:
玉米支链淀粉融于纯净水配成质量百分比10%的溶液,添加5U/g的商业化异淀粉酶,在30℃水浴反应12h,加热灭酶活、离心处理后,将上清液喷雾干燥即得支链淀粉链酶切水解产物。
称取一定质量的支链淀粉链酶切水解产物溶解于纯净水配成质量百分比浓度20mg/mL,按照1:20比例将海藻糖添加到上述溶液,混合均匀;置于30℃水浴加热60min后,然后加入400U/g罗伊氏蔗糖酶并保温反应3h;加热灭酶活、膜滤分级、离心处理,将所获得上清液进行干燥即得功能糖。
所得功能糖的平均分子尺寸为DP 20.1,接枝率为61%。
所得功能糖在L细胞系模型中刺激肠道激素GLP-1释放水平1.18pM/μg蛋白。
实施例5探究不同淀粉类糊精供体对所得功能糖的性能影响
参照实施例1,将淀粉类糊精供体由直链淀粉链酶切水解产物替换为表1所示的未进行处理的直链淀粉,其他条件不变,制得相应的功能糖。所得功能糖在L细胞系模型中GLP-1释放水平结果见表1。
参照实施例3,将淀粉类糊精供体由β-环糊精开环解聚产物替换为表1所示的未进行处理的β-环糊精,其他条件不变,制得相应的功能糖。所得功能糖在L细胞系模型中GLP-1释放水平结果见表1。
参照实施例4,将淀粉类糊精供体由支链淀粉链酶切水解产物替换为表1所示的未进行处理的支链淀粉,其他条件不变,制得相应的功能糖。所得功能糖在L细胞系模型中GLP-1释放水平结果见表1。
表1不同淀粉类糊精供体所得功能糖的功效结果
淀粉类糊精供体 | 接枝率 | L细胞系模型中GLP-1释放水平 |
直链淀粉 | 18% | 0.25pM/μg蛋白 |
β-环糊精 | 3% | 0.08pM/μg蛋白 |
支链淀粉 | 32% | 0.35pM/μg蛋白 |
由表1可知,未经过酶切处理、直接利用直链淀粉、β-环糊精、支链淀粉制备功能糖,所得功能糖在L细胞系模型中刺激肠道激素GLP-1释放水平远小于1.05pM/μg蛋白。
实施例6探究不同多功能酶系用量对所得功能糖的性能影响
参照实施例1,将α-4,3-葡糖基转移酶的用量由100U/g分别替换为80U/g、600U/g,制得相应的功能糖产品。所得功能糖产品的性能结果见表2。
表2不同多功能酶系用量所得功能糖的功效结果
用量(U/g) | L细胞系模型中GLP-1释放水平 |
80 | 0.53pM/μg蛋白 |
600 | 1.01pM/μg蛋白 |
实施例7探究不同多功能酶系用量对所得功能糖的性能影响
参照实施例1,将直链淀粉链酶切水解产物的质量浓度由10mg/mL分别替换为2mg/mL、5mg/mL、60mg/mL,制得相应的功能糖产品。所得功能糖产品的性能结果见表3。
表3混合液中不同淀粉类糊精供体的质量浓度所得功能糖的功效结果
混合液质量浓度(mg/mL) | L细胞系模型中GLP-1释放水平 |
2 | 0.19pM/μg蛋白 |
5 | 0.53pM/μg蛋白 |
60 | 0.70pM/μg蛋白 |
对比例1
参照肠道激素GLP-1测定过程,直接将麦芽糖醇、甘露糖和海藻糖分布在L细胞系模型中进行测定,相应十分结果如表4所示。
表4功能单糖在L细胞系模型中GLP-1释放水平结果
单糖 | L细胞系模型中GLP-1释放水平 |
麦芽糖醇 | 0.39pM/μg蛋白 |
甘露糖 | 0.61pM/μg蛋白 |
海藻糖 | 0.53pM/μg蛋白 |
可见,功能单糖也能刺激GLP-1的分泌,但是GLP-1释放水平远小于1.05pM/μg蛋白。
本发明所描述的具体实施案例仅作为对本发明精神和部分实验做举例说明。本发明所述领域的技术人员可以对所描述的具体实施案例做出各种各样的修改或补充或采用类似的方式替代,但并不会偏离本发明的精神或者超越所附权利要求书所定义的范围。
Claims (10)
1.一种制备用于调节肠促胰岛素定位释放的功能糖的方法,其特征在于,所述方法是将淀粉类糊精供体和功能单糖受体分散于水中,混匀,形成混合液;然后加入多功能酶制剂进行酶解,结束后,即可获得可调节肠促胰岛素定位释放的功能糖;
其中,所述的功能单糖受体选自如下任意一种或多种:2-脱氧葡萄糖、甘露糖、岩藻糖、阿洛糖、海藻糖、塔格糖、麦芽糖醇、甘露醇;
多功能酶制剂选自如下任意一种或多种:蔗糖-4-葡糖基转移酶、蔗糖-6-葡糖基转移酶、蔗糖-1,6(3)-α-葡聚糖6(3)-葡糖基转移酶、α-4,6-葡糖基转移酶、α-4,3-葡糖基转移酶、罗伊氏蔗糖酶。
2.根据权利要求1所述的方法,其特征在于,所述混合液中淀粉类糊精供体的浓度为5-50mg/mL。
3.根据权利要求1所述的方法,其特征在于,所述混合液中淀粉类糊精供体与功能单糖受体的质量比为1:1-1:20。
4.根据权利要求1所述的方法,其特征在于,所述多功能酶制剂相对底物淀粉类糊精的添加量为100-500U/g。
5.根据权利要求1所述的方法,其特征在于,所述淀粉类糊精是通过采用如下方法制备得到:采用对淀粉链进行酶切水解;或者对环化糊精进行开环解聚获得线性糊精。
6.根据权利要求5所述的方法,其特征在于,所述酶切水解过程中包括添加150-200U/gα-淀粉酶,或者5-10U/g异淀粉酶;所述环化糊精过程中包括添加80-100U/g新普鲁兰酶。
7.权利要求1-6任一项所述方法制备得到的一种用于调节肠促胰岛素定位释放的功能糖。
8.根据权利要求7所述的用于调节肠促胰岛素定位释放的功能糖,其特征在于,所述用于调节肠促胰岛素定位释放的功能糖中功能单糖受体在淀粉类糊精上的接枝率为40-80%。
9.根据权利要求7所述的用于调节肠促胰岛素定位释放的功能糖,其特征在于,所述可调节肠促胰岛素定位释放的功能糖的平均分子尺寸为DP 3-30。
10.权利要求7-9任一项所述的用于调节肠促胰岛素定位释放的功能糖在制备糖尿病特膳食品、轻断食产品、运动食品、低升糖食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010995718.4A CN112111538B (zh) | 2020-09-21 | 2020-09-21 | 一种可调节肠促胰岛素定位释放的功能糖及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010995718.4A CN112111538B (zh) | 2020-09-21 | 2020-09-21 | 一种可调节肠促胰岛素定位释放的功能糖及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112111538A true CN112111538A (zh) | 2020-12-22 |
CN112111538B CN112111538B (zh) | 2022-05-10 |
Family
ID=73800755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010995718.4A Active CN112111538B (zh) | 2020-09-21 | 2020-09-21 | 一种可调节肠促胰岛素定位释放的功能糖及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112111538B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114081180A (zh) * | 2021-11-26 | 2022-02-25 | 江南大学 | 一种脂溶性组分递送系统及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919668A (en) * | 1994-06-02 | 1999-07-06 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Non-reducing saccharide and its production and use |
CN104171800A (zh) * | 2014-08-08 | 2014-12-03 | 山东百龙创园生物科技有限公司 | 一种低聚异麦芽糖与低聚果糖复合颗粒及其制备方法 |
CN104480160A (zh) * | 2014-11-21 | 2015-04-01 | 江南大学 | 一种利用环糊精葡萄糖基转移酶生产偶合糖的方法 |
CN110055233A (zh) * | 2019-04-19 | 2019-07-26 | 江南大学 | 一种热稳定性提高的MTSase突变体及其应用 |
-
2020
- 2020-09-21 CN CN202010995718.4A patent/CN112111538B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919668A (en) * | 1994-06-02 | 1999-07-06 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Non-reducing saccharide and its production and use |
CN104171800A (zh) * | 2014-08-08 | 2014-12-03 | 山东百龙创园生物科技有限公司 | 一种低聚异麦芽糖与低聚果糖复合颗粒及其制备方法 |
CN104480160A (zh) * | 2014-11-21 | 2015-04-01 | 江南大学 | 一种利用环糊精葡萄糖基转移酶生产偶合糖的方法 |
CN110055233A (zh) * | 2019-04-19 | 2019-07-26 | 江南大学 | 一种热稳定性提高的MTSase突变体及其应用 |
Non-Patent Citations (6)
Title |
---|
FRANCISCO J. PLOU等: "Glucosyltransferases acting on starch or sucrose for the synthesis of oligosaccharides", 《CANADIAN JOURNAL OF CHEMISTRY》 * |
HIRA, T等: "Resistant maltodextrin promotes fasting glucagon-like peptide-1 secretion and production together with glucose tolerance in rats", 《BRITISH JOURNAL OF NUTRITION》 * |
LEE HS等: "Cooperative action of alpha-glucanotransferase and maltogenic amylase for an improved process of isomaltooligosaccharide (IMO) production", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》 * |
孔刘娟: "抗性糊精制备方法、功能特性及在食品中应用研究", 《中国食品添加剂》 * |
李炳学等: "酶法合成功能性低聚糖", 《微生物学杂志》 * |
李玉等: "功能性低聚糖合成中糖基转移酶研究进展", 《食品科学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114081180A (zh) * | 2021-11-26 | 2022-02-25 | 江南大学 | 一种脂溶性组分递送系统及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112111538B (zh) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103719880B (zh) | 高活性紫甘薯膳食纤维的制备方法 | |
US20200332326A1 (en) | Green preparation methods of rice resistant starch | |
CN104987422B (zh) | 用氨基酸修饰的玉米淀粉衍生物的制备方法 | |
JP2016506719A (ja) | セリポリア・ラセラタの培養液抽出物の調製方法およびこれから調製されたセリポリア・ラセラタの培養液抽出物を有効成分として含有する糖尿病性疾患および糖尿病合併症の予防または治療用の薬学的組成物 | |
CN106318991A (zh) | 一种抗性糊精及其制备方法 | |
US11214629B2 (en) | Method for preparing short-clustered dextrin | |
KR102381709B1 (ko) | 식이섬유의 제조방법 | |
CN106755234B (zh) | 一种绿茶降血糖肽的制备方法及其应用 | |
CN112111538B (zh) | 一种可调节肠促胰岛素定位释放的功能糖及其制备方法 | |
CN111172221A (zh) | 一种改性淀粉的制备方法及应用 | |
CN105441511A (zh) | 一种高粱抗性淀粉的制备方法 | |
CN110862461A (zh) | 一种抗性糊精制备方法 | |
CN104397587A (zh) | 一种高含量慢消化淀粉(sds)的天然富硒米片的制备方法 | |
CN106519048A (zh) | 一种提高淀粉中慢消化淀粉含量的方法 | |
Um et al. | Slow digestion properties of long-sized isomaltooligosaccharides synthesized by a transglucosidase from Thermoanaerobacter thermocopriae | |
CN112385840B (zh) | 一种低gl谷物源营养特膳食品及其加工方法 | |
WO2019128258A1 (zh) | 一种慢消化糖的制备方法 | |
CN114190560A (zh) | 一种降尿酸功能食品及其制备方法 | |
CN107712531A (zh) | 一种青稞酶解液的制备方法 | |
CN103689047A (zh) | 一种易于消化饼干的制备方法 | |
CN116114876B (zh) | 一种含甘蔗多酚与莱茵衣藻的降血糖组合物及其制备方法 | |
CN109805233B (zh) | 一种具有提升免疫力功效的茯苓饮料及其制备方法 | |
CN103432183B (zh) | 翠菊中多酚提取物及其制备方法和用途 | |
WO2013166859A1 (zh) | 魔芋保健消渴胶囊及其制备方法 | |
JP6157706B2 (ja) | セリポリア・ラセラタの培養液抽出物の調製方法およびこれから調製されたセリポリア・ラセラタの培養液抽出物を有効成分として含有する糖尿病性疾患および糖尿病合併症の予防または治療用の薬学的組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |